MDRA yields 9732.36% · ABBV yields 3.06%● Live data
📍 MDRA pulled ahead of the other in Year 1
Combined, MDRA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MDRA + ABBV for your $10,000?
Medra Corporation engages in the acquisition, development, and commercial exploitation of hydrogen-based technologies. The company primarily concentrates on fuel cells, hydrogen-specific sensors, and hydrogen safety. It seeks out technologies, secures those technologies through licensing agreements with the patent holders, and converts the technologies into viable products that it then produces and sells. DCH manufactures and sells a line of hydrogen sensors that are both mobile (a hand held unit) and stationary (wall ceiling or conduit mounted units) to a range of industries and customers. The company also develops, manufactures, and sells fuel cells that range from 12 watts to five kilo watts. Its H2SCAN hydrogen-specific sensing systems offer an alternative to gas detectors used in various industries, including food processing, petrochemical production, semiconductor manufacturing, and glass and metals processing. The company has licenses to various technologies, including The Robust Hydrogen Sensor, The Thick Film Hydrogen Sensor, and The Proton Exchange Membrane Fuel Cell. Medra Corporation was founded in 1994 and is based in Valencia, California.
Full MDRA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.